Aim: Whether timing of catheterization (immediate versus delayed intervention) in high risk ACS has an impact on outcome in patients with RF is not known.
Results: Eight (2.3%) patients had severe RF, 67 (19.4%) moderate RF and 270 (78.3%) no RF. Baseline characteristics were well matched except for a lower multivessel disease rate in the "primary PCI" strategy group (52% vs 85%, p=0.008) in the moderate RF group. Patients received intense antiplatelet therapy with a mean 660 mg (±268) clopidogrel loading dose followed by a 111 mg (±40) maintenance dose, while 99% of the PCI patients received abciximab. LMWH were used in 68% of patients and radial approach was predominant (84%). The mean peak of troponin did not differ according to the revascularization strategy wathever the renal function. The 30-day rate of death, MI and urgent revascularization were higher in RF patients but did not differ significantly between the two revascularization strategies whatever the renal function. Recurrent ischemia was however significantly more frequent in the moderate RF group undergoing deferred catheterization in comparison with a primary PCI strategy (33,3% vs. 8.8%, p= 0.014). Major bleeding complications were similar whatever the strategy in the different renal function groups.
Conclusion:
Although renal failure is associated with more ischemic complications, the timing of intervention appears to have no impact on outcome of these patients. Thus, the primary results of the ABOARD study apply also to renal failure patients.
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Immediate prognosis of STEMI complicated by cardiogenic shock requiring circulatory assist device. About 2700 patients in the Regional Acute Myocardial Infarction Registry of Brittany (ORBI).
Guillaume Leurent (1), Emmanuelle Filippi (2), Pierre Yves Pennec (3), Jean Philippe Hacot (4), Benoit Moquet (5), Antoine Rialan (6), Gilles Rouault (7), Philippe Druelles (8), Marc Bedossa (1), Dominique Boulmier (1), Isabelle Coudert (9), Hervé Le Breton (1 Purpose: Recent improvement in management of), and notably reduction of delays to coronary reperfusion, allowed a decrease of the incidence of ischemic. Moreover, (CAD) are more and more accessible. This study aims at determining the actual epidemiology and intra-hospital prognosis of ST-Elevation Myocardial Infarction (STEMI) complicated by cardiogenic shock (CS) requiring circulatory assist device (CAD).
Methods:
We analyzed data collected between June 06 and September 09 in the "Observatoire Régional Breton sur l'Infarctus (ORBI)", a registry of all patients admitted to an interventional cardiology centre of Brittany in the acute phase of a STEMI, within 24 h of symptoms onset. Main clinical data and intra hospital outcome were compared between ORBI patients requiring CAD for CS (group 1) and those who didn't require CAD (group 2).
Results:
Among 2700 patients included in the ORBI registry, 101 patients (3.7 %) required CAD: intra aortic balloon pump (IABP), 93 patients (3.4 %), extra corporal life support (ECLS), 2 patients (0.07%), IABP and ECLS, 6 patients (0.2%). Main clinical data are summarized in table 1. Group 1 mortality was high (38%), compared to the low mortality in group 2 (4%, p<0.0001). Mean length of hospitalisation was significantly higher in the group 1 than in the group 2 (respectively 8.9 ± 7 and 6.7 ± 4 days, p=0.03). Factors associated with CAD requiring were: age, anterior area STEMI, coronary angioplasty, three-vessel or left main coronary artery disease and haemoJanuary 15 th , Saturday 2011 Background: The impact of hypoxia on left ventricular (LV) myocardial contractility remains debated. Objectives: We hypothesized that acute hypoxia in healthy people increases LV twist as a consequence of the cardiovascular adaptation to stress (increased sympathetic nerve activity). Because hypoxia increases heart rate, we aimed to control for this change by studying the same subjects under atropine during normoxia.
Methods:
We studied 21 subjects (mean age: 27 ± 7 years) without medical history. Echocardiography was performed in normoxia and after 30 minutes of hypoxia (12% FiO 2 ). Short axis basal and apical views were analyzed using speckle tracking software. LV twist was defined as the net difference between the apical and basal rotation. The effect of atropine on LV twist was tested in the same subjects under normoxia.
Results:
As expected, hypoxic breathing decreased arterial saturation in oxygen below 80% (table). Peak LV twist increased, as did heart rate, LV ejection fraction (LVEF) and systolic mitral annular velocity. Despite a decrease in mitral E/A ratio, early diastolic LV untwisting (at 5%, 10% and 15% of diastole) was not significantly modified under hypoxia. Atropine did not alter peak systolic twist (8.9 ± 3.1˚ versus 10.1 ± 2.6˚,p=0.09, without and with atropine, respectively), despite an increase in heart rate (from 64 ± 11 to 77 ± 11 beats/min, p=0.0001). Conclusions: Acute hypoxia increases LV twist as well as other parameters of LV contractility. This change in LV twist does not result from the chronotropic effect of hypoxia.
Predictors and prognostic value of contrast-induced nephropathy in patients undergoing primary angioplasty
Antonio Gaspar, Joao Costa, Vitor Ramos, Silvia Ribeiro, Catarina Vieira, Sérgio Nabais, Sergia Rocha, Pedro Azevedo, Miguel Pereira, Alberto Salgado, Adelino Correia Hospital de Braga, Cardiologie, Braga, Portugal Purpose: Contrast-induced nephropathy (CIN) after coronariography has been associated to increased morbidity and mortality. Patients submitted to primary angioplasty seem to be at higher risk for CIN development, owing in part to hemodynamic status. We sought to determine the prevalence, predictors and prognostic value of CIN occurrence after primary angioplasty.
Methods: A total of 141 patients consecutively submitted to primary angioplasty and admitted to our coronary unit were reviewed. CIN was defined as impairment of renal function occurring within 48 hours after administration of contrast media and manifested by an absolute increase in the serum creatinine level of at least 0.5 mg/dl or by a relative increase of at least 25% over the baseline value (in the absence of another cause). The primary end points were in-hospital and six-month mortality.
Results: CIN developed in 18.4% of the patients (n=26). Patients with CIN were older (68 ± 13 vs 61 ± 13 years; p <0.05) and more often had diabetes mellitus (38.5% vs 15.7%; p <0.05). Although statistical significance was not reached, there was a trend for higher prevalence of hypertension (61.5% vs 42.6%; p=0.09), female gender (30.8% vs 18.3%; p=0.18) and Killip class higher than one at admission (26.9% vs 16.3%; p=0.1) among patients with CIN. Patients with CIN had an higher mean time from symptoms to reperfusion (304 ± 192 vs 397 ± 206 minutes; p <0.04) . By multivariate analysis, independent correlates of CIN were older age (OR=1.04; 95%CI=1.01 -1.08) and diabetes mellitus (OR=2.99; 95%CI=1.08 -8.3). Patients with CIN had higher in-hospital (19.2% vs 0.9%; p <0.05) and 6-month mortality (28.6% vs 4.9%; p <0.05).
Conclusions: CIN was a frequent complication of primary angioplasty (18.4% of the patients). Independent predictors of CIN after primary angioplasty were older age and diabetes mellitus. Patients with CIN had a worse prognosis, both during in-hospital stay and at 6 months.
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Use of recombinant factor VIIa (NovoSeven) in patients treated with fondaparinux for ongoing life-threatening bleeding Francois Schiele (1), Paul Luporsi (1), Nicolas Meneveau (1), Evelyne Racadot (2), Vincent Descotes-Genon (1), Romain Chopard (1), MarieFrance Seronde (1), Sebastien Janin (1) (1) CHU de Besançon, Cardiologie, Besançon, EFS Bourgogne-Franche Comte, Besançon, France Background: Recombinant factor VIIa (rFVIIa) may be used to reverse the anticoagulant effect of fondaparinux. We report a single centre experience in 8 patients with severe bleeding.
Methods: Patients pretreated with fondaparinux, with life-threatening bleeding were treated with 90µg/kg rFVIIa. Life-threatening bleeding was defined as TIMI 3 bleeding or a drop in hemoglobin > 5g or hemodynamic shock and elevated antiXa activity. Endpoints were (1) death (2) persistent bleeding (clinical or continued drop of hemoglobin) (3) uncontrolled hemodynamic shock (4) clinical arterial or venous thrombosis and (5) peak of thrombin generation.
Results: Between June 2008 and November 2009, among 1224 patients treated with fondaparinux, 8 presented with life-threatening bleeding (3 with venous thrombo-embolic disease, 5 acute coronary syndrome (ACS)). Patients with ACS had double (n=2) or triple (n=3) antiplatelet therapy. Bleedings were related to vascular access in 5, gastro-duodenal in 2 and lung in 1. Five patients had hemorrhagic shock, mean drop in hemoglobin was 6.1 g/dL. AntiXa activity ranged from 0.67 to 1.62, rFVIIa dose ranged from 3.6 to 7.65mg. One patient died from uncontrolled shock, no patient had signs of persistent bleeding or thrombotic complication. In patients with the highest basal anti-Xa activity (1.14 to 1.62), the time to peak of thrombin generation remained low. 
Values are means (SD)
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